01-09-03 05PH 1634

EXPRESS MAIL NO. EV207702975US

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → [+]

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	09/757,417
Filing Date	January 8, 2001
First Named Inventor	Gary R. Fanger
Group Art Unit	1634
Examiner Name	Bradley L. Sisson
Attorney Docket No.	210121.479C1

ENCLOSURES (*check all that apply*)

- [ ] Fee Transmittal Form
- [ ] Fee Attached
- [ ] Amendment/Response
  - [ ] After Final
  - [ ] Affidavits/declaration(s)
- [ ] Extension of Time Request
- [ ] Express Abandonment Request
- [x] Supplemental Information Disclosure Statement; Form PTO-1449
- [x] Cited Reference
- [ ] Certified Copy of Priority Document(s)
- [ ] Response to Missing Parts under 37 C.F.R. 1.52 or 1.53
- [ ] Response to Missing Parts/Incomplete Application
- [ ] Assignment Papers (*for an Application*)
- [ ] Drawing(s)
- [ ] Request for Corrected Filing Receipt
- [ ] Licensing-related Papers
- [ ] Petition
- [ ] Petition to Convert to a Provisional Application
- [ ] Power of Attorney, Revocation, Change of Correspondence Address
- [ ] Declaration
- [ ] Statement under 37 CFR 3.73(b)
- [ ] Terminal Disclaimer
- [ ] Small Entity Statement
- [ ] Request for Refund
- [ ] CD(s), Number of CD(s) _____
- [ ] After Allowance Communication to Group
- [ ] Appeal Communication to Board of Appeals and Interferences
- [ ] Appeal Communication to Group (*Appeal Notice, Brief, Reply Brief*)
- [ ] Proprietary Information
- [ ] Status Letter
- [x] Return Receipt Postcard
- [x] Additional Enclosure(s) (*please identify below*):

Copy of Invitation to Pay Additional Fees for PCT/US02/03057

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Carol D. Laherty, Ph.D. 51,909	00500 PATENT TRADEMARK OFFICE
Signature	Carol Laherty	
Date	January 6, 2003	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name		
Signature		Date:

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC
SUITE 6300
701 FIFTH AVENUE
SEATTLE WASHINGTON 98104-7092

PCT

INVITATION TO PAY ADDITIONAL FEES

(PCT Article 17(3)(a) and Rule 40.1)

Date of Mailing *(day/month/year)*: 17 October 2002

Applicant's or agent's file reference: 210121.47901PC

PAYMENT DUE within 15 days from the above date of mailing

International application No.: PCT/US02/03057

International filing date *(day/month/year)*: 08 JANUARY 2002

Applicant: CORIXA CORPORATION

1. This International Searching Authority

(i) considers that there are 42 *(number of)* inventions claimed in the international application covered by the claims indicated below/on an extra sheet:
Please See Extra Sheet.

and it considers that **the international application does not comply with the requirements of unity of invention** (Rules 13.1, 13.2 and 13.3) for the reasons indicated below/on an extra sheet:
Please See Extra Sheet.

(ii) ☐ has carried out a partial international search (see Annex) ☒ will establish the international search report on those parts of the international application which relate to the invention first mentioned in claims Nos.: 1(in part) and 2-5

(iii) will establish the international search report on the other parts of the international application only if, and to the extent to which, additional fees are paid.

2. The applicant is hereby **invited**, within the time limit indicated above, to pay the amount indicated below:

$ 210.00	X	41	=	$ 8610.00
Fee additional per invention		number of additional inventions		total amount of additional fees

The applicant is informed that, according to Rule 40.2(c), **the payment of any additional fee may be made under protest**, i.e., a reasoned statement to the effect that the international application complies with the requirement of unity of invention or that the amount of the required additional fee is excessive.

3. ☐ Claim(s) Nos. _____ have been found to be unsearchable under Article 17(2)(b) because of defects under Article 17(2)(a) and therefore have not been included with any invention.

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer
SUSAN UNGAR

Telephone No. (703) 308-0196

Form PCT/ISA/206 (July 1992)★

INVITATION TO PAY ADDITIONAL FEES

International application No.
PCT/US02/03057

1. This International Search Authority has found 42 inventions claimed in the International Application covered by the claims indicated below:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group 1, claim(s)1-5, drawn to an isolated polypeptide comprising at least 7 consecutive amino acid residues of SEQ ID NO:27, residues 21-40.
Group 2, claim(s) 1-5, drawn to an isolated polypeptide comprising at least 7 consecutive amino acid residues of SEQ ID NO:27, residues 61-80.
Group 3, claim(s) 1-5, drawn to an isolated polypeptide comprising at least 7 consecutive amino acid residues of SEQ ID NO:50.
Group 4, claim(s)6, drawn to a method of inhibiting development of breast cancer comprising administer a composition comprising at least 7 consecutive amino acid residues of SEQ ID NO;27, residues 21-40.
Group 5, claim(s) 6, drawn to a method of inhibiting development of breast cancer comprising administer a composition comprising at least 7 consecutive amino acid residues of SEQ ID NO;27, residues 61-80.
Group 6, claim(s) 6, drawn to a method of inhibiting development of breast cancer comprising administer a composition comprising at least 7 consecutive amino acid residues of SEQ ID NO:50.
Groups 7-12, claim(s)7-11 drawn to a diagnostic kit comprising one or more polypeptides according to claim 1 and a detection reagent comprising a reporter group. It is noted that by factorial analysis, the invention is drawn to six different combinations of polypeptides which are distinct inventions. Applicant must elect a single invention, a single polypeptide or combination of polypeptides for examination.
Group 13, claim(s) 12-13 drawn to a method for removing tumor cells from a biological sample comprising contacting a biological sample with T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 21-40.
Group 14, claim(s) 12-13, drawn to a method for removing tumor cells from a biological sample comprising contacting a biological sample with T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 61-80.
Group 15, claim(s)12-13, drawn to a method for removing tumor cells from a biological sample comprising contacting a biological sample with T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:50.
Group 16, claim(s) 14, drawn to a method for inhibiting the development of breast cancer comprising administering to a patient a biological sample treated with T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 21-40.
Group 17, claim(s) 14, drawn to method for inhibiting the development of breast cancer comprising administering to a patient a biological sample treated with T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 61-80.
Group 18, claim(s)14, drawn to method for inhibiting the development of breast cancer comprising administering to a patient a biological sample treated with T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:50.
Group 19, claim(s) 15, drawn to a method for stimulating and/or expanding T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 21-40.
Group 20, claim(s) 15, drawn to a method for stimulating and/or expanding T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 61-80.
Group 21, claim(s)15, drawn to a method for stimulating and/or expanding T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:50.
Group 22, claim(s) 16, drawn to isolated T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 21-40.
Group 23, claim(s) 16, drawn to isolated T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 61-80.
Group 24, claim(s)16, drawn to isolated T cells that specifically react with at least 7 consecutive amino acids of SEQ ID NO:50.
Group 25, claim(s)17-18, drawn to a method for inhibiting the development of breast cancer comprising administering to a patient an effective amount of a T cell population that specifically reacts with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 21-40.
Group 26, claim(s) 17-18, drawn to drawn to a method for inhibiting the development of breast cancer comprising administering to a patient an effective amount of a T cell population that specifically reacts with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 61-80.
Group 27, claim(s)17-18, drawn to drawn to a method for inhibiting the development of breast cancer comprising administering to a patient an effective amount of a T cell population that specifically reacts with at least 7 consecutive

amino acids of SEQ ID NO:50.
Group 28, claim(s) 19, drawn to a method for inhibiting the development of breast cancer comprising administering to a patient an effective amount of a T cell population wherein at least one proliferated cell that specifically reacts with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 21-40 has been cloned.
Group 29, claim(s) 19, drawn to a method for inhibiting the development of breast cancer comprising administering to a patient an effective amount of a T cell population wherein at least one proliferated cell that specifically reacts with at least 7 consecutive amino acids of SEQ ID NO:27, amino acids 61-80 has been cloned.
Group 30, claim(s)19, drawn to a method for inhibiting the development of breast cancer comprising administering to a patient an effective amount of a T cell population wherein at least one proliferated cell that specifically reacts with at least 7 consecutive amino acids of SEQ ID NO:50 has been cloned.
Group 31-36, claim(s) 20-21, drawn to six distinct polypeptides SEQ ID NOs 46, 51-55.
Group 37-42, claim(s) 22-23, drawn to six distinct polypeptides, SEQ ID NOs 47 and 56-60.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups 1-42 do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking groups i-42 appears to be that they all relate to an isolated polypeptide comprising at least 7 consecutive amino acid residues of SEQ ID NO:27, residues 21-20.

However, WO20007338 specifically teaches human mammaglobin peptide Pro5, SEQ ID NO:3 which is a 31 amino acid peptide comprising 21 amino acid residues of SEQ ID NO:27, including amino acids 20-33 os SEQ ID NO:27 (see attached sequence database search pct-us02-03057a-27, result 36).

Therefore, the technical feature linking the inventions of Groups 1-42 does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

The special technical feature of Group 1 is considered to be an isolated polypeptide comprising at least 7 consecutive amino acid residues of SEQ ID NO:27,residues 21-40. All of the other groups are drawn to products and methods relate to different inventive concepts.

Accordingly, Groups 1-42 are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.